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106 Poster Session IIBackground: The HCT-CI is a comorbidity score adapted to
hematopoietic cell transplantation, which has identified 3 risk
groups with increased non-relapse mortality (NRM) and lower
overall survival (OS) (Blood 2005;106:2912). We determined the
HCT-CI score in a cohort of patients who underwent myeloabla-
tive MUD transplantation in an single institution trial. Methods:
The analysis included all patients undergoing MUD transplant
from 1996–2006 who received a 3-drug GVHD prophylaxis regi-
men. Comorbidities were obtained by retrospective chart review
and scored according to the HCT-CI score. Results: 150 patients
(median age 40) were included, with 38% low-, 34% intermediate-
and 28% high-risk disease, per CIBMTR classification. Diagnoses
included acute leukemia in 50%, MDS in 12%, CML in 15%,
and lymphoma in 18%. Conditioning regimens were Cy-TBI in
64% and Bu-Cy in 21%. HCT-CI scores of 0, 1–2 or $3 were
found in 17%, 30% and 53% of patients. The majority of comor-
bidities were pulmonary (72%). Day 100 and 5-year OS were 82.7
and 33%, with a 23% and 50.4% cumulative incidence of NRM.
Five year relapse-related mortality was 15.8%. No statistically
significant differences in NRM or OS were detected using the
HCT-CI grouping of 0, 1–2 and $3. Unadjusted hazard ratio
(HR) for inferior survival were 0.9 (CI 0.47–1.85, P 5 .79) and
1.65 (CI 0.885–3.090, P5 .11) for scores 1–2 and$3, respectively.
We determined an alternate prognostic model based on 2 groups.
Statistical modeling separated patients with a score of 0–3 (n 5
97, 64%) and $4 (n 5 53, 35.6%), with a 3 month and 5 year OS
of 84% and 45% versus 52% and 10%, respectively (P\ .0001).
Cumulative incidence of day 100 and 5-year NRM was 16% and
38% versus 43% and 73%, respectively. UnadjustedHR for inferior
survival was 2.77 (CI 1.816–4.225, P\ .0001) for a score of$4. By
multivariate analysis, only the HCT-CI score (P\ .0001) and the
disease risk per CIBMTR (P 5 .0058) were predictive of OS and
NRM, but not age, CMV status, sex- or HLA-mismatch, or regi-
men. Conclusions: Although the HCT-CI score was predictive
of NRM and OS in this high-risk cohort, we were unable to detect
statistically significant differences between the 3 risk groups defined
in the original score. A modified 2-group scoring system of 0–3 and
$4, respectively, identified a low-risk and a high-risk group. This
simplified, 2-tiered scoring system will have utility in clinical deci-
sion-making and in defining patients eligible for clinical trials.286
LIPOPOLYSACCHARIDE BINDING PROTEIN PROMOTER VARIANTS IN-
FLUENCE THE RISK FOR GRAM-NEGATIVE BACTEREMIA AND MORTAL-
ITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Chien, J.W., Boeckh, M., Hansen, J.A., Clark, J.G. Fred Hutchinson
Cancer Research Center, Seattle, WA.
Lipopolysaccharide binding protein (LBP) function is dependent
upon circulating LBP levels. Disturbance of LBP transcription reg-
ulation may influence the risk for clinical events. We comprehen-
sively assessed the LBP sequence and identified three haplotype
tagging single nucleotide polymorphisms (SNPs) for our studies.
Using a nested case control design, we assessed whether genetic var-
iation in the LBP gene influences the risk for Gram-negative (GN)
bacteremia after allogeneic hematopoietic cell transplantation
(HCT), then confirmed the associations by prospectively assessing
association with an intermediate phenotype (circulating LBP levels)
and a secondary clinical phenotype (mortality). Presence of the SNP
6878 C allele among patients was associated with a two-fold higher
risk for GN bacteremia (odds ratio 2.22, p5 0.001). SNP 6878 was
in strong linkage disequilibrium with three SNPs in the LBP pro-
moter, one of which was SNP 6878 (r25 0.8), located in a promoter
CAAT box. The SNP 1683 C allele was associated with higher me-
dian circulating LBP levels (TT 10.86 6 0.68 mg/ml; TC 13.86 6
1.51 mg/ml; CC 20.66 6 5.89 mg/ml; p 5 0.002) and a three-fold
increase in mortality risk (hazard ratio 3.30, p 5 0.001). These
data suggest that genetic variation in the LBP promoter variation
likely influences the risk for developing GN bacteremia and death
after HCT.287
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR CHEMORADIO-
THERAPY-RELATED MYELODYSPLASTIC SYNDROME AND ACUTE LEU-
KEMIA: A SINGLE-CENTER ANALYSIS OF 47 PATIENTS
Yokoyama, H., Fukuda, T., Kobayashi, Y., Kim, S.-W., Maruyama, D.,
Mori, S.-I., Watanabe, T., Tanosaki, R., Tajima, K., Tobinai, K.,
Takaue, Y. National Cancer Center Hospital, Tokyo, Japan.
Purpose: To examine the value of allogeneic HCT in the treat-
ment of therapy-related myelodysplastic syndrome/acute leukemia
(t-MDS/t-AL) which develops after previous exposure to chemo-
therapy (CT) or radiotherapy. Patients and Methods: We retro-
spectively analyzed the data of 47 patients who were treated at
our institution between 1996 and 2007. The primary diseases in-
cluded malignant lymphoma (n 5 17), breast cancer (n 5 13) and
other solid tumors (n5 17). The median interval between the diag-
nosis of the primary disease and the onset of t-MDS/t-AL was 3.9
years (range, 0.6–18.7). Twenty-five patients had AML, 5 ALL, 1
biphenotypic acute leukemia, and 16 MDS. Results: Thirty-three
patients received disease-adapted CT, with a response rate of
73%, while 14 patients were elected to receive no interventions
due to an indolent clinical course such as MDS-RA (n 5 13).
With a median follow-up of surviving patients of 1.9 years (range,
0.05–10.5) after the diagnosis of t-MDS/t-AL, the 3-year OS for
all patients was 55%. Twenty-seven patients (median age, 47 years:
range, 3–63) underwent allogeneic HCT from related (n 5 12) or
unrelated (n 5 15) donors after myeloablative (n 5 18) or re-
duced-intensity (n 5 9) conditioning regimens. The sources of
stem cells were BM in 15 patients, PBSC in 10, and CB in 2. At
the time of HCT, 18 t-MDS/t-AL were in CR, 1 was in non-CR,
and 8 had untreated t-MDS. Twenty patients (43%) did not un-
dergo HCT due to various reasons, including age older than 65
years (n 5 11), indolent clinical course (n 5 4), progression of the
primary disease (n 5 4) or t-AL (n 5 3), and patient refusal (n 5
2). The 3-year OS was significantly better in patients who received
HCT than in those who did not (71% vs 31%; P 5 0.018). TRM
after HCT was 15%. The 3-year OS was better in those who
achieved CR after initial therapy for t-MDS/t-AL than in those
who did not (74% vs 30%; P 5 0.002). A multivariate analysis re-
vealed that HCT was associated with a significantly better OS,
even after adjusting for age and other significant prognostic factors
including achievement of CR in t-MDS/AL, cytogenetic risk group,
and an interval between the diagnosis of primary disease and t-
MDS/t-AL of longer than 3 years.Conclusion:Although this study
is contaminated by a selection bias, it still appears that HCT was an
effective therapeutic option for patients with t-MDS/t-AL, espe-
cially when patients were in CR.These results support a prospective
study to examine the value of upfront HCT.288
HEALTHY ALLOGENEIC RELATED DONORS OF PERIPHERAL HAEMATO-
POIETIC PROGENITORS: A LONG-TERM PROSPECTIVE STUDY
Tassi, C.1, Arpinati, M.2, Giudice, V.1, Bontadini, A.1. 1Sant’Orsola-
Malpighi Policlinic, Bologna, Italy; 2Sant’Orsola-Malpighi Policlinic,
Bologna, Italy.
One hundred and thirty six healthy donors who underwent
aphaeresis collections after G-CSF stimulation have been included
in a surveillance protocol for a provisional period of ten years. Once
a year, they are required to send aWBC, Hb and platelets count re-
port and clinical information to our Service. To date, the mean ob-
servation time is 46(4–120) months. Fifty out of the 136 donors
show a follow-up longer than 60 months. As previously described
(1), at day 114 after G-CSF administration, a moderate neutrope-
nia or lymphocytopenia, have been documented in 32 and 20 sub-
jects, respectively. Moreover, a mild thrombocytopenia has been
diagnosed during the G-CSF administration in 52 donors. After
a five years period of observation, a persistent, slight reduction of
circulating neutrophils or lymphocytes has been detectable in 5/
32 or 5/20 donors, without clinical relevance. As regards clinical
data, 1 case of MGUS, Insipid Diabetes, Autoimmune Thyroiditis,
Multiple Sclerosis, Intestinal Multiple Polyps and Allergy to certain
food, were the main diseases reported by six donors. Four donors
Poster Session II 107are females, two males. The mean age is 42(26–60) and the mean
follow-up is 7 (3–9) years. Although tumours have not been de-
scribed in this group of donors, nevertheless theG-CSF administra-
tion in patients with Multiple Sclerosis has been frequently
correlated with a worsening of the clinical status (2,3). Moreover,
the G-CSF therapy seems to exacerbate the recurrence of autoim-
mune diseases, as described in other published surveys (4).
Taken together, these data seem to confirm and underline the
need of a long-term clinical and haematological surveillance period
of healthy subjects stimulated with G-CSF. Nevertheless, the sur-
veillance duration has not been definitely fixed: ten years of follow-
up could be a too short period to lead to significant information on
the potential induction or enhancement of pathological conditions.
Bibliography: (1): Bone Marrow Transplantation, 36: 289–294,
2005; (2): Neurology, 54: 2147–2150, 2000; (3): J Neuroimmunol,
2006; (4): Bone Marrow Transplantotion 2001; 28: 1–12.
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IMPACT OF LONGITUDINAL LONG TERM TRANSPLANT CLINIC (LTTC)
ON SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT (SCT)
Jagasia, M.1, Clifton, C.1, Vaughan, L.A.1, Chinratanalab, W.1,
Chen, H.2, Dixon, S.1, Hunt, C.1, Kassim, A.1. 1Vanderbilt University
Medical Center, Nashville, TN; 2Vanderbilt University Medical Center,
Nashville, TN.
Introduction: Allogeneic SCT patients (pts.) are followed inten-
sively for 100 days after SCT at the transplant center (TC). The
ideal model of follow-up after day 100 is not well studied. Pts. are
often transitioned back to their primary hematologist at the TC
(or in community). We hypothesized that a longitudinal LTTC su-
pervised by transplant physicians and mid-level providers and care
coordinated with consultants in other disciplines would improve
outcome.Methods:We established LTTC in 1/2006. All pts. after
allogeneic SCT (.day 100) were transitioned to LTTC (group[G]
1: transition day\120). Some pts. were transitioned after day 120 or
were referred by their primary hematologist to LTTC (G2). G3 was
a historical group of pts. with survival of at least 150 days after SCT
(care provided by primary hematologist). Overall survival (OS) was
measured from transition to LTTC for G1 and 2 and from day 150
for G3. Results:G 1, 2 and 3 had 43, 31 and 114 pts., respectively.
Groups were comparable for age at SCT, donor status, and disease
risk (CIBMTRdefinition).More pts. inG3 (74%) had ablative SCT
compared to G1 (51%) and G2 (65%) (P5 0.019). Median follow-
up time was different (G1: 349 days, G2: 966 days, G3: 765 days, P
\0.0001).MedianOSwas 1905 days (95%CI 1143–2664). TheOS
for the 3 groups were different (P5 0.001). 1-yr. OS forG 1, 2 and 3
were 80%, 88%, and 59%. There were 4, 2, and 55 deaths in the 3
groups (non-relapse mortality: 0%, 50%, and 37%). In univariate
analyses (G1 1 2 vs.3), donor type (P 5 0.045), risk status (P 5
0.0012) and group status based on LTTC (time dependent variable)
(P 5 0.0478) were significant predictors of OS. Using Cox-regres-
sion analyses (adjusted for transplant age, donor type, transplant
type), risk status (low vs. high risk) (HR 2.82, P 5 0.0005) and
LTTC status (HR 1.97, P 5 0.047) were significant predictors of
OS. Using Cox-regression analyses (G1 vs. 3) risk status (low vs.
high risk) (HR 2.74, P 5 0.0012) and LTTC status (HR 3.27, P
5 0.0251) were significant predictors of OS.Conclusion:Although
limited by retrospective nature, short follow up in G1 and compar-
ision to a historical control, our study shows that pts. followed in the
LTTC clinic with coordinated care from consultants had a better
OS compared with pts. who were followed prior to LTTCbeing es-
tablished. The impact of LTTC clinic on other long-term trans-
plant problems (viz. diabetes, dyslipidemias, osteoporosis, sexual
dysfunction) will be studied.
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PRE-TRANSPLANT SEUM C-PEPTIDE LEVEL PREDICTS FOR POST-
TRANSPLANT DIABETES MELLITUS (PTDM) AFTER ALLOGENEIC STEM
CELL TRANSPLANT (SCT)
Jagasia, S.1, Perkins, J.1, Survant, M.1, Chen, H.2, Jagasia, M.3. 1Van-
derbilt Univeristy Medical Center, Nashville, TN; 2Vanderbilt Univer-
isty Medical Center, Nashville, TN; 3Vanderbilt Univeristy Medical
Center, Nashville, TN.The incidence of newonset PTDMafter an allogeneic SCT is un-
known.Weconducted aprospective study inpatients (pts.) undergo-
ing allogeneic SCT with cyclosporine based graft-versus-host
disease (GVHD) prophylaxis to identify risk factors for PTDM.
Methods: Non diabetic pts. meeting screening criteria were en-
rolled. Demographics including family history, race, past history
of transient diabetes and body-mass index were obtained. Baseline
fasting samples included blood glucose (BG), lipid profile, serum
fructosamine, serum C-peptide and insulin. Pts. had weekly fasting
BG. PTDM was defined by standard criteria. Systemic steroids
(SS) were used to treat GVHD. Results: Median age of pts. (20
males, 17 females) was 43 yrs. (range, 21–66). Median FBG was
97 mg/dL (range, 80–119). 22 of 37 pts. (60%) developed DM at
a median of 41 days post SCT (range, 8–93). 14 of 37 pts (38%)
completed study until day 100 without developing DM and 1 pa-
tient died prior to day 100 without PTDM. In univariate analyses,
the only pre-transplant variable that predicted for PTDM was se-
rum C-peptide and serum insulin levels. Pts. with PTDM had
higher pre-transplant serumC-peptide level compared to pts. with-
out PTDM (4.68, 95% CI 3.76 to 5.66 vs. 2.29, 95% CI 1.87 to
2.71, P\0.0001). Pts. with PTDMhad higher mean pre-transplant
serum insulin level compared to pts. without PTDM (22.86, 95%
CI 16.44 to 29.33 vs. 10.57, 95% CI 6.64 to 14, P\ 0.0001). 13
of 21 (61%) pts. who received SS developed PTDM compared
with 9 of 16 (56%) who did not receive SS (P 5 0.729). In a multi-
variable Cox-regression analyses (adjusted for SS use), C-peptide
was an independent predictor of PTDM (HR 1.264; 95% CI
1.06–1.50, P 5 0.008). The interaction between C-peptide and SS
was significant. In subgroup analyses of pts. without SS, C-peptide
had aHRof 1.89 (95%CI 1.16–3.06, P5 0.009), and in pts. with SS
the HR was 1.15 (95% CI 0.94–1.4, P 5 0.161). Conclusion: Our
study shows that PTDMoccurs in 60% of pts. after allogeneic SCT
and in 56% of pts. without SS use. Pre-transplant C-peptide level is
an independent risk factor, especially in patients without SS use.
The exact etiology of PTDM in pts. without SS use is not known.
Perhaps, a pre-transplant higher C-peptide level identifies patients
at risk for metabolic stress following allogeneic SCT. It is well es-
tablished that elevatedC-peptide and insulin levels are hallmark fea-
tures of insulin resistant states and early type 2 diabetes.291
COMPARISON OF OUTCOMES IN CHILDREN UNDERGOING A SINGLE AL-
LOGENEIC TRANSPLANT USING BONE MARROW (BM) OR UMBILICAL
CORD BLOOD (UCB) AS STEM CELL SOURCE. THE CHILDREN’S MEMO-
RIAL HOSPITAL EXPERIENCE
Merchant, M.1, Huang, W.1, Kletzel, M.1,2. 1Children’s Memorial Hos-
pital, Chicago, IL; 2Northwestern University Feinberg School of Medi-
cine, Chicago, IL.
Objective: To evaluate differences in transplant outcomes be-
tween recipients of BM and UCB.Method:We evaluate 137 trans-
plants with BM and 119 UCB at Children’s Memorial Hospital,
between 1992 and 2007. BM: 122 MR, 15 MUD; 108 pts (78.8%)
had malignancies (ALL n 5 55, AML n 5 31, others n 5 22),
46% were in first complete remission (CR1), 28.5% in $ CR 2,
and 8% in partial remission (PR). 29 (21.2%) had non-malignant
conditions (THAL 5 7, Aplastic Anemia 5 8, SCIDS 5 2, others
5 12). 67.9% received myeloablative conditioning (fTBI, VP-Cy,
or Thiotepa); 32.1% had reduced intensity conditioning (RIC)
(VP/Cy, Bu/FLU/, 6 ATG). 52 female, 85 male; age 9.2 yrs (0.2–
23); weight 30.4 kg (4–85.1). HLA matching, 6/6 (100), 5/6 (28),
4/6 (9). Median TNC infused was 1.96  108/kg, 1.22  108/kg
MNC, 7.45 106/kgCD34.UCB: 82 pts (68.9%) hadmalignancies
(ALL n5 40, AMLn5 24, others n5 18), 36.1% inCR1, 25.2% in
$CR2, 7.6% in PR. 37 pts (31.1%) had non-malignant conditions
(SCIDS n5 11, THAL n5 3, Aplastic Anemia n5 2, others5 21).
79% received myeloablation (fTBI/VP/Cy for malignancies, fTBI/
CY 6Thiotepa for non-malignant); 21% had RIC (VP/Cy or Bu/
FLU/6 ATG). 53 female, 66 male; age 5.4 yrs (0.1–20.6), weight
15.7 kg (4–73). HLA matching 6/6 (12) 5/6 (29) 4/6 (70) 3/6 (8).
Cell dose infused was 0.8  108/kg TNC, 0.55  108/kg MNC,
0.78  06/kg CD34. Result/Outcome: BM: 86.3% achieved
ANC (.500 cells/mL), 88.4% achieved PLT count (.20,000
cells/mL) at median of 18.3 days (10–71) and 32.9 days (4–222)
